scholarly journals Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review

2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Harun Khan ◽  
Andrew Hill ◽  
Janice Main ◽  
Ashley Brown ◽  
Graham Cooke
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Ribonucleic Acid ◽  
Scale Up ◽  
Virus Antigen ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Chain Reaction ◽  
Antigen Tests

Abstract The complexity and cost of current diagnostics for hepatitis C virus (HCV) may act as a prevention to the scale-up of treatment in the developing world. Currently, ribonucleic acid (RNA)-polymerase chain reaction tests are the gold standard. However, there is potential for the use of simpler and cheaper antigen tests to confirm HCV infection in different clinical settings. We evaluated the sensitivity and specificity of antigen assays. This was compared with the reference-standard RNA assays. A subanalysis also assessed Architect core antigen test, which is the only commercially available antigen test on the market. In 24 datasets, evaluating HCV-antigen assays in 8136 samples, the percentage of HCV-antigen positive, HCV-RNA negative was 0.57%. The percentage HCV-antigen negative, HCV-RNA positive was 3.52%. There is strong evidence that antigen detection performs as well as RNA-based assays for HCV management. The use of antigen tests could improve access to HCV care in underresourced healthcare settings.

scholarly journals SP315ARCHITECT HEPATITIS C VIRUS (HCV) CORE ANTIGEN TEST: A HCV RNA SCREENING ALTERNATIVE IN END-STAGE RENAL DISEASE (ESRD) AND HEMODIALYSIS PATIENTS?

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i450-i450
Author(s):  
Rita Valério Alves ◽  
Rita Abrantes ◽  
Hernâni Gonçalves ◽  
Maria Leonor Gonçalves ◽  
Karina Lopes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Stage Renal Disease ◽  
End Stage

Serologic, Virologic, and Histologic Characteristics of Chronic Phase Hepatitis C Virus Disease in Children Infected by Transfusion

PEDIATRICS ◽  
1994 ◽  
Vol 94 (6) ◽  
pp. 919-922
Author(s):  
Suguru Matsuoka ◽  
Katsuyoshi Tatara ◽  
Yasunobu Hayabuchi ◽  
Yoshiyuki Taguchi ◽  
Kazuhiro Mori ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Acute Infection ◽  
Chronic Phase ◽  
Hcv Infection ◽  
Core Antigen ◽  
Hcv Rna ◽  
Histologic Evidence ◽  
Group A ◽  
Group B

Objective. We studied the time course of hepatic dysfunction, seropositivity to hepatitis C virus (HCV) antibodies, viremia, and histologic evidence of hepatic injury to evaluate the course of HCV infection in children infected by blood transfusion. Patients and methods. Twenty-nine patients (ages 4 to 18 years) who underwent open-heart surgeries for congenital heart disease were grouped into three categories based on alterations in serum alanine aminotransferase (ALT) levels: Group A, acute infection; Group B, subacute infection; and Group C, chronic infection. Results. In Group C, all 13 patients had detectable HCV RNA in serum. In contrast, all patients in Group A had no detectable HCV RNA. In Group B, one of nine patients had detectable HCV RNA and two of four patients examined had persistent chronic hepatitis by histologic criteria. Antibodies directed against C100-3 antigen or core-antigen were more useful than second-generation HCV antibody assays in determining the relationship between viremia and immunologic response. Infection with HCV genotype II and the presence of higher HCV RNA copy numbers were associated with histologic evidence of hepatic damage. Conclusion. An abnormal ALT value is frequently associated with viremia, and biochemically resolved acute infection reflects clearance of HCV. However, a normal ALT does not always reflect an absence of hepatocyte damage and HCV replication in patients with subacute disease. The measures outlined in this study are useful indicators of disease activity during the chronic phase of post-transfusion HCV infection.

Isolate antibody to hepatitis C virus core antigen (C22) by RIBA-2: correlation with HCV-RNA and anti-NS5

1993 ◽  
pp. 219-228 ◽  
Author(s):  
G. Taliani ◽  
M. C. Badolato ◽  
R. Lecce ◽  
R. Bruni ◽  
C. Clementi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Core Antigen ◽  
Hcv Rna ◽  
Virus Core

scholarly journals Hepatitis C virus core antigen test in virological monitoring of patients on long-term dialysis

2010 ◽  
Vol 3 (3) ◽  
pp. 334-334
Author(s):  
G. Li Cavoli ◽  
C. Zagarrigo ◽  
O. Schillaci ◽  
A. Tralongo ◽  
U. Rotolo
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Core Antigen ◽  
Antigen Test ◽  
Virus Core ◽  
Virological Monitoring

scholarly journals Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient

2011 ◽  
Vol 1 (2) ◽  
pp. 28
Author(s):  
Emanuele Durante-Mangoni ◽  
Domenico Iossa ◽  
Umberto Malgeri
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Response To Treatment ◽  
Core Antigen ◽  
Hcv Rna ◽  
Virus Genotype ◽  
Viral Kinetics ◽  
Genotype 5

Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory changes and advanced liver fibrosis. The patient had a high viral load but a small serum level of hepatitis C core antigen. On combination antiviral treatment with pegylated-interferon alpha 2a, 180 ?g/week, and ribavirin, 1200 mg/day, the patient experienced an impressive reduction in serum HCV RNA as early as day 2 of treatment and eventually became a sustained virological responder. Our viral kinetics data support previous clinical studies showing HCV genotype 5 could be as intrinsically sensitive to interferon as HCV genotypes 2 and 3.

scholarly journals PREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS AND EVALUATION OF HCV-CORE ANTIGEN TEST IN SCREENING PATIENTS FOR DIALYSIS IN SANA'A CITY, YEMEN

2019 ◽  
Author(s):  
Samira H Hanash ◽  
Hassan A. Al-Shamahy ◽  
Mohammed Hussein Saleh Bamshmous
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
General Population ◽  
Predictive Power ◽  
Hcv Infection ◽  
Health Concern ◽  
Core Antigen ◽  
Antigen Test ◽  
Genotype 4 ◽  
Hcv Core Antigen

Hepatitis C virus infection is a constant worldwide public health concern. The prevalence of HCV infection is higher in patients on chronic haemodialysis (HD) than in the general population. Despite the control of blood products, hepatitis C virus transmission is still being observed among patients undergoing dialysis. Detection systems for serum HCV antibodies are insensitive in the acute phase because of the long serological window. Direct detection of HCV depends on PCR test but this test is not suitable for routine screening. The objective of this study was to determine prevalence of HCV, genotyping and if HCV core antigen test could be a better alternative to NAT techniques for the diagnosis of HCV infection during the window period and whether the sensitivity for antibody detection is preserved. We screened 159 patients on long-term dialysis by HVC antibodies test, PCR HCV-RNA and HCV core antigen test by commercial tests. The prevalence of HCV was 10.7% (17 patients) and genotype 4 was the most common one (64.7%). The sensitivity of HCV core antigen test was 94.1%, the specificity 100%, the positive predictive power 100%, and the negative predictive power 97.9%. In conclusions; patients on maintenance HD in Yemen have a high prevalence of HCV infection comparing with general population; and genotype 4 is predominant. The performance of serological detection of HCV core antigen was better than that of HCV antibodies test and may be an alternative to nucleic acid amplification technology (NAT) for routine monitoring of patients on chronic dialysis.

Sign in / Sign up

Export Citation Format

Share Document